BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 18437437)

  • 1. Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany.
    Schürmann D; Sorensen SV; De Cock E; Duttagupta S; Resch A
    Eur J Health Econ; 2009 Feb; 10(1):65-79. PubMed ID: 18437437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of linezolid versus vancomycin for hospitalized patients with complicated skin and soft-tissue infections in France.
    De Cock E; Sorensen S; Levrat F; Besnier JM; Dupon M; Guery B; Duttagupta S
    Med Mal Infect; 2009 May; 39(5):330-40. PubMed ID: 19304423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of linezolid vs. vancomycin in treating methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections using a decision analytic model.
    Bounthavong M; Hsu DI; Okamoto MP
    Int J Clin Pract; 2009 Mar; 63(3):376-86. PubMed ID: 19222624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
    McKinnon PS; Sorensen SV; Liu LZ; Itani KM
    Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis.
    Bounthavong M; Zargarzadeh A; Hsu DI; Vanness DJ
    Value Health; 2011; 14(5):631-9. PubMed ID: 21839399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis.
    Bounthavong M; Hsu DI
    Curr Med Res Opin; 2010 Feb; 26(2):407-21. PubMed ID: 20001574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections.
    Patanwala AE; Erstad BL; Nix DE
    Curr Med Res Opin; 2007 Jan; 23(1):185-93. PubMed ID: 17257479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patients.
    McCollum M; Sorensen SV; Liu LZ
    Clin Ther; 2007 Mar; 29(3):469-77. PubMed ID: 17577468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria.
    Eckmann C; Lawson W; Nathwani D; Solem CT; Stephens JM; Macahilig C; Simoneau D; Hajek P; Charbonneau C; Chambers R; Li JZ; Haider S
    Int J Antimicrob Agents; 2014 Jul; 44(1):56-64. PubMed ID: 24928311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).
    Itani KM; Weigelt J; Li JZ; Duttagupta S
    Int J Antimicrob Agents; 2005 Dec; 26(6):442-8. PubMed ID: 16289514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus.
    Sharpe JN; Shively EH; Polk HC
    Am J Surg; 2005 Apr; 189(4):425-8. PubMed ID: 15820454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany.
    De Cock E; Krueger WA; Sorensen S; Baker T; Hardewig J; Duttagupta S; Müller E; Piecyk A; Reisinger E; Resch A
    Infection; 2009 Apr; 37(2):123-32. PubMed ID: 19277465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.
    Stein GE; Wells EM
    Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of linezolid in methicillin-resistant Staphylococcus aureus skin and skin structure infections.
    Bounthavong M; Hsu DI
    Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):683-98. PubMed ID: 23252352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infections.
    Laohavaleeson S; Barriere SL; Nicolau DP; Kuti JL
    Pharmacotherapy; 2008 Dec; 28(12):1471-82. PubMed ID: 19025428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus.
    Itani KM; Dryden MS; Bhattacharyya H; Kunkel MJ; Baruch AM; Weigelt JA
    Am J Surg; 2010 Jun; 199(6):804-16. PubMed ID: 20227056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillin-resistant Staphylococcus aureus-complicated skin and soft tissue infections: a retrospective, propensity score-matched, case-control analysis.
    Itani KM; Biswas P; Reisman A; Bhattacharyya H; Baruch AM
    Clin Ther; 2012 Aug; 34(8):1667-73.e1. PubMed ID: 22770644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
    Estes L; Orenstein R
    Clin Ther; 2007 Feb; 29(2):381-3; author reply 383-4. PubMed ID: 17472831
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
    Estes L; Orenstem R
    Clin Ther; 2007 Apr; 29(4):759-60; author reply 760-1. PubMed ID: 17617300
    [No Abstract]   [Full Text] [Related]  

  • 20. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.
    Stevens DL; Herr D; Lampiris H; Hunt JL; Batts DH; Hafkin B
    Clin Infect Dis; 2002 Jun; 34(11):1481-90. PubMed ID: 12015695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.